Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 16/20 | 0.43 |
| ▸ | THRB | P10828 | 16/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5354531 | 0.86 | CYP3A4 (0.40) | THRATHRBCYP3A4CYP2C19 | |
| SCHEMBL5282266 | 0.84 | THRA (0.47) | THRATHRBCYP3A4CYP2C19 | |
| SCHEMBL5964570 | 0.84 | THRA (0.46) | THRATHRBCYP3A4CYP2C19 | |
| SCHEMBL5367322 | 0.84 | THRA (0.62) | THRATHRBCYP3A4CYP2C19 | |
| SCHEMBL5367327 | 0.84 | THRA (0.62) | THRATHRBCYP3A4CYP2C19 | |
| SCHEMBL5355142 | 0.83 | THRB (0.54) | THRATHRBCYP3A4 | |
| SCHEMBL5351674 | 0.83 | THRA (0.48) | THRATHRBCYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL5353832 | 0.82 | THRA (0.46) | THRATHRB | |
| SCHEMBL12312830 | 0.82 | THRA (0.50) | THRATHRBCYP3A4CYP2C19 | |
| SCHEMBL5351679 | 0.82 | THRA (0.43) | THRATHRBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279593-B2 | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | KARO BIO AB (SE) | 2007-10-09 | — | — | US | disclosed |
| US-20050107347-A1 | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | KARO BIO AB (SE) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107347-A1 | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | TSHR, THRB, THRA | THRA 3/4885THRB 2/4885CYP3A4 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.